BRPI0817503A2 - Derivados de purina substituídos por pirimidina - Google Patents

Derivados de purina substituídos por pirimidina

Info

Publication number
BRPI0817503A2
BRPI0817503A2 BRPI0817503-9A BRPI0817503A BRPI0817503A2 BR PI0817503 A2 BRPI0817503 A2 BR PI0817503A2 BR PI0817503 A BRPI0817503 A BR PI0817503A BR PI0817503 A2 BRPI0817503 A2 BR PI0817503A2
Authority
BR
Brazil
Prior art keywords
pyrimidine
purine derivatives
substituted purine
substituted
derivatives
Prior art date
Application number
BRPI0817503-9A
Other languages
English (en)
Inventor
Harish Kumar Mysore Nagaraj
Meredith Williams
Original Assignee
S Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Bio Pte Ltd filed Critical S Bio Pte Ltd
Publication of BRPI0817503A2 publication Critical patent/BRPI0817503A2/pt
Publication of BRPI0817503B1 publication Critical patent/BRPI0817503B1/pt
Publication of BRPI0817503B8 publication Critical patent/BRPI0817503B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0817503A 2007-10-05 2008-10-03 derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa BRPI0817503B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97772007P 2007-10-05 2007-10-05
US7553208P 2008-06-25 2008-06-25
PCT/SG2008/000379 WO2009045175A1 (en) 2007-10-05 2008-10-03 Pyrimidine substituted purine derivatives

Publications (3)

Publication Number Publication Date
BRPI0817503A2 true BRPI0817503A2 (pt) 2015-05-05
BRPI0817503B1 BRPI0817503B1 (pt) 2019-10-29
BRPI0817503B8 BRPI0817503B8 (pt) 2021-05-25

Family

ID=40030252

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817503A BRPI0817503B8 (pt) 2007-10-05 2008-10-03 derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa

Country Status (17)

Country Link
US (3) US8247410B2 (pt)
EP (1) EP2209786B1 (pt)
JP (2) JP5479346B2 (pt)
KR (3) KR20160116045A (pt)
CN (2) CN104119336B (pt)
AU (1) AU2008307798B2 (pt)
BR (1) BRPI0817503B8 (pt)
CA (1) CA2701581C (pt)
DK (1) DK2209786T3 (pt)
ES (1) ES2406129T3 (pt)
HK (2) HK1145832A1 (pt)
IL (2) IL204804A (pt)
MX (1) MX2010003668A (pt)
MY (1) MY150993A (pt)
RU (2) RU2518098C2 (pt)
WO (1) WO2009045175A1 (pt)
ZA (1) ZA201003118B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
MX2010003668A (es) 2007-10-05 2010-07-02 S Bio Pte Ltd Derivados de purina sustituidas con primidina.
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
CA2730271A1 (en) 2008-07-07 2010-01-14 Xcovery Holding Company Llc Pi3k isoform selective inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
AU2009314544C1 (en) * 2008-11-11 2015-11-12 Xcovery Holding Company Llc PI3K/mTOR kinase inhibitors
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2414362B1 (en) * 2009-04-03 2014-06-11 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (s) inhibitors
WO2010114494A1 (en) * 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
EP3072890B1 (en) 2009-07-07 2018-10-17 MEI Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011078795A1 (en) * 2009-12-21 2011-06-30 S*Bio Pte Ltd Bridged morpholino substituted purines
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
WO2012172043A1 (en) 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
CA2857601A1 (en) * 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
SG11201602446VA (en) * 2013-10-16 2016-05-30 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
PT3080103T (pt) * 2013-12-11 2018-07-23 Sunesis Pharmaceuticals Inc Compostos de biaril úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
WO2015089327A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016109426A1 (en) * 2014-12-29 2016-07-07 Verastem, Inc. Oral dosing regimen of a dual mtor and pi3 inhibitor
CN105985354B (zh) * 2015-02-09 2020-10-02 南京盖特医药技术有限公司 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
WO2016157074A1 (en) 2015-03-30 2016-10-06 Daiichi Sankyo Company, Limited 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
KR101589900B1 (ko) 2015-07-30 2016-01-29 강영만 바닥설치용 경계구
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
US10010555B2 (en) * 2016-06-02 2018-07-03 Celgene Corporation Animal and human anti-trypanosomonal and anti-leishmania agents
AU2017286380B2 (en) * 2016-06-16 2021-02-04 Janssen Pharmaceutica Nv Azabenzimidazole derivatives as PI3K beta inhibitors
TWI777992B (zh) 2016-12-02 2022-09-21 日商第一三共股份有限公司 新穎內-β-N-乙醯基胺基葡萄糖苷酶
EP3621604A4 (en) * 2017-03-31 2021-01-13 FTG Bio LLC SALINE FORMS OF PURINE AMINO PYRAZINE SELECTIVE KINASE INHIBITOR
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
SG11202001258UA (en) 2017-08-14 2020-03-30 Mei Pharma Inc Combination therapy
JP7071588B2 (ja) 2018-09-27 2022-05-19 シャンハイ インリー ファーマシューティカル カンパニー リミテッド モルホリノキナゾリン系化合物の結晶形の結晶、その製造方法、使用および医薬品組成物
BR112021010715A2 (pt) 2018-12-20 2021-11-16 Ksq Therapeutics Inc Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
TW202233621A (zh) 2020-10-30 2022-09-01 美商Ｋｓｑ治療公司 經取代吡唑并嘧啶之固態形式及其用途
WO2024041519A1 (zh) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 一种吗啉基喹唑啉类化合物、其药物组合物及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617304A (en) 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
US4772606A (en) 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
HUP0100931A3 (en) * 1998-02-26 2002-08-28 Aventis Pharma Inc 6,9-disubstituted 2-[trans-(-aminocyclohexyl)amino]purines and pharmaceutical compositions containing them
DE60144322D1 (de) * 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
JP4102664B2 (ja) * 2000-07-19 2008-06-18 ノバルティス アクチエンゲゼルシャフト バルサルタン塩
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
AU2002342051B2 (en) 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
EP1551410A2 (en) 2002-09-06 2005-07-13 Smithkline Beecham Corporation Novel compounds
WO2004035740A2 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
SI2316831T1 (sl) * 2002-11-21 2013-07-31 Novartis Ag 2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka
CA2507100C (en) * 2002-11-21 2012-10-09 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
JP5321061B2 (ja) 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
GB0519245D0 (en) 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043031A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
US20110009403A1 (en) 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
MX2010003668A (es) 2007-10-05 2010-07-02 S Bio Pte Ltd Derivados de purina sustituidas con primidina.
TW200938201A (en) 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
RU2509081C2 (ru) 2008-05-30 2014-03-10 Дженентек, Инк. Пуриновые соединения, ингибирующие рi3к, и способы применения
WO2009157880A1 (en) 2008-06-27 2009-12-30 S*Bio Pte Ltd Pyrazine substituted purines
CA2730271A1 (en) 2008-07-07 2010-01-14 Xcovery Holding Company Llc Pi3k isoform selective inhibitors
WO2010114494A1 (en) 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
EP2414362B1 (en) 2009-04-03 2014-06-11 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (s) inhibitors

Also Published As

Publication number Publication date
IL235555A0 (en) 2014-12-31
MX2010003668A (es) 2010-07-02
JP5479346B2 (ja) 2014-04-23
CN104119336A (zh) 2014-10-29
HK1145832A1 (en) 2011-05-06
CN104119336B (zh) 2016-08-24
RU2518098C2 (ru) 2014-06-10
ES2406129T3 (es) 2013-06-05
ZA201003118B (en) 2011-08-31
US8247410B2 (en) 2012-08-21
EP2209786B1 (en) 2013-02-27
JP5885729B2 (ja) 2016-03-15
EP2209786A1 (en) 2010-07-28
CA2701581A1 (en) 2009-04-09
RU2014110894A (ru) 2015-07-10
JP2014139159A (ja) 2014-07-31
CA2701581C (en) 2016-12-20
CN101889015B (zh) 2014-06-04
IL204804A (en) 2014-11-30
KR20160116045A (ko) 2016-10-06
KR101701109B1 (ko) 2017-02-13
KR20150063171A (ko) 2015-06-08
HK1203488A1 (en) 2015-10-30
IL235555B (en) 2019-08-29
AU2008307798A1 (en) 2009-04-09
IL204804A0 (en) 2010-11-30
DK2209786T3 (da) 2013-06-03
JP2010540625A (ja) 2010-12-24
WO2009045175A1 (en) 2009-04-09
CN101889015A (zh) 2010-11-17
BRPI0817503B1 (pt) 2019-10-29
US20140066620A1 (en) 2014-03-06
US8609838B2 (en) 2013-12-17
MY150993A (en) 2014-03-31
RU2681081C2 (ru) 2019-03-04
US20100298319A1 (en) 2010-11-25
KR20100075609A (ko) 2010-07-02
AU2008307798B2 (en) 2013-10-03
BRPI0817503B8 (pt) 2021-05-25
RU2010117737A (ru) 2011-11-10
US20130079512A1 (en) 2013-03-28
KR101643237B1 (ko) 2016-07-27

Similar Documents

Publication Publication Date Title
BRPI0817503A2 (pt) Derivados de purina substituídos por pirimidina
BRPI0923815A2 (pt) Síntese de nucleosídeos de purina
BRPI0923195A2 (pt) compostos purina
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0819797A2 (pt) compostos de nucleosídeos antivirais
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
ES2465673T9 (es) Derivados de pirimidina
BRPI0811014A2 (pt) Veículo
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0914544A2 (pt) derivados de pirimidona substituídos
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
BRPI0821258A2 (pt) Derivados de ciclopropilamina
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona
CR10520A (es) Derivados de purina como agonistas de a2a
DE602008000135D1 (de) Hintere Fahrzeugstruktur
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: VERASTEM, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.